A1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä
Predictive value of p53, Ki67 and TLR5 in neoplastic progression of Barrett’s esophagus : a matched case-control study (2022)

Helminen, O., Melkko, J., Saarnio, J., Sihvo, E., Kuopio, T., Ohtonen, P., Kauppila, J. H., Karttunen, T. J., & Huhta, H. (2022). Predictive value of p53, Ki67 and TLR5 in neoplastic progression of Barrett’s esophagus : a matched case-control study. Virchows Archiv, 481(3), 467-476. https://doi.org/10.1007/s00428-022-03340-5

JYU-tekijät tai -toimittajat

Julkaisun tiedot

Julkaisun kaikki tekijät tai toimittajat: Helminen, Olli; Melkko, Jukka; Saarnio, Juha; Sihvo, Eero; Kuopio, Teijo; Ohtonen, Pasi; Kauppila, Joonas H.; Karttunen, Tuomo J.; Huhta, Heikki

Lehti tai sarja: Virchows Archiv

ISSN: 0945-6317

eISSN: 1432-2307

Julkaisuvuosi: 2022

Ilmestymispäivä: 26.05.2022

Volyymi: 481

Lehden numero: 3

Artikkelin sivunumerot: 467-476

Kustantaja: Springer

Julkaisumaa: Saksa

Julkaisun kieli: englanti

DOI: https://doi.org/10.1007/s00428-022-03340-5

Julkaisun avoin saatavuus: Avoimesti saatavilla

Julkaisukanavan avoin saatavuus: Osittain avoin julkaisukanava

Julkaisu on rinnakkaistallennettu (JYX): https://jyx.jyu.fi/handle/123456789/81627

Tiivistelmä

Barrett’s esophagus progresses to high-grade dysplasia or cancer along the well-established metaplasia-dysplasia-adenocarcinoma sequence. The aim of this study was to evaluate the value of p53, Ki67, and toll-like receptor 5 (TLR5) in prediction of malignant progression of Barrett’s metaplasia and low-grade dysplasia. This was a retrospective matched case–control study based on Northern and Central Finland population. Patients diagnosed with esophageal high-grade dysplasia or adenocarcinoma were included. From these patients, all previous endoscopy samples were obtained along with original diagnostic HE-slides and clinical data. Age- and sex-matched patients with non-progressing Barrett’s metaplasia and low-grade dysplasia confirmed with follow-up endoscopies were used as controls. Two gastrointestinal pathologist re-reviewed all original HE-slides, and newly made sections to confirm representative tissue material blinded from clinical data. p53, Ki67, and TLR5 were immunohistochemically stained. Final cohort included 45 patients with progressive Barrett’s metaplasia (n = 21) or low-grade dysplasia (n = 24), and 92 patients with non-progressive Barrett’s metaplasia (n = 52) or low-grade dysplasia (n = 40). In Barrett’s metaplasia, aberrant p53 expression was observed in 6% of samples in progressors and 0% in non-progressors. In low-grade dysplasia, aberrant p53 was seen in 56% of samples in progressors and 17% in non-progressors (Odd’s ratio 6.7, 95% CI 1.8–24.6). Ki67 or TLR5 showed no association with disease progression. In this matched case–control study, p53 expression associated with a high risk of malignant progression in Barrett’s low-grade dysplasia. Routine staining of p53 is indicated in expert confirmed low-grade dysplasia.

YSO-asiasanat: ruokatorvisyöpä; biomarkkerit; proteiinit; antigeenit; immunohistokemia; tarkkailu

Vapaat asiasanat: Barrett’s esophagus; esophageal adenocarcinoma; dysplasia marker; immunohistochemistry; surveillance

Liittyvät organisaatiot

OKM-raportointi: Kyllä

Raportointivuosi: 2022

JUFO-taso: 1